GlobeNewsWire
07 Dec 2025, 23:00 UTC · 42w ago
Verdict
Headline takes no side. We score SLS +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
SELLAS Life Sciences reported a 46% overall response rate (CR+CRi+MLFS) for SLS009 in combination with AZA/VEN in patients with relapsed/refractory AML-MR.
So whatPositive Phase 2 efficacy data in a difficult-to-treat cancer population is a primary catalyst for biotech valuation increases.
More positive than 99% of claims this week
The median overall survival (mOS) in the least pretreated cohort reached 8.9 months, significantly exceeding the expected 2.6 months for this population.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 98% of claims this week
The combination therapy demonstrated strong response rates in high-risk patients harboring ASXL1 (48%) and TP53 (57%) mutations.
More positive than 93% of claims this week
No dose-limiting toxicities (DLTs) or treatment-related deaths were observed during the study.
More positive than 87% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company presented positive Phase 2 data showing clinically meaningful activity and high overall response rates for its drug candidate SLS009.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
+561.5%
Price agrees with the score
$11.51 vs $1.74 close before publication (Dec 5) · not market-adjusted
SLS chart →
